Sahajanand Medical IPO Day 3: GMP ₹43

Welcome back to our daily IPO updates! Today marks Day 3 of the Sahajanand Medical IPO subscription period, and it’s time to dive into the latest figures and sentiment. As the IPO window for this mainboard offering on the NSE continues to be open, investors are closely watching every move. With the issue price set at ₹344 per share and a lot size of 43 shares, the anticipation is palpable. Let’s break down what the current subscription status and Grey Market Premium (GMP) tell us about Sahajanand Medical’s journey to the stock exchange.

Subscription Status

As we enter the crucial final days of the subscription, the subscription numbers for Sahajanand Medical are currently standing at 0x across all categories: Retail, Non-Institutional Investors (NII), and Qualified Institutional Buyers (QIB). This is an interesting development. Typically, by Day 3, we’d expect to see at least some initial traction, especially in the retail segment. The complete absence of subscriptions so far, while potentially concerning for some, could also indicate a wait-and-watch approach from investors. Many prefer to gauge the overall demand in the latter half of the subscription period before committing their capital. The QIB and NII segments remaining at 0x also suggests that the larger institutional players haven’t made their significant bids yet. This doesn’t necessarily mean they won’t; it’s common for them to place their orders closer to the closing date. The bottom line here is that the real picture of demand will likely emerge in the next 48 hours.

GMP Update

Moving on to the Grey Market Premium (GMP), Sahajanand Medical’s GMP has remained steady at ₹43 for today, mirroring yesterday’s figure. This stability, while not showing an upward surge, is itself a positive signal. A consistent GMP indicates that the market sentiment towards the IPO hasn’t wavered negatively. Based on this GMP, the expected listing price is around ₹387 (Issue Price ₹344 + GMP ₹43). This represents a potential listing gain of approximately 12.5%, which is a decent return for investors looking for short-term gains. However, remember that GMP is an unofficial indicator and can fluctuate. It’s a reflection of market sentiment, but not a guarantee of listing performance. The fact that it hasn’t dropped is encouraging.

Should You Apply?

So, the million-dollar question: should you apply for the Sahajanand Medical IPO? The subscription data on Day 3 is a blank slate, which is unusual but not necessarily a deal-breaker. It suggests that the market is waiting for more clarity or perhaps investors are strategically holding back. The GMP, however, paints a more optimistic picture, hinting at a healthy listing. The expected listing price of ₹387 offers an attractive potential upside. That said, it’s always prudent to conduct your own due diligence. Consider the company’s fundamentals, its future prospects, and the overall market conditions. The IPO period runs until October 19th, 2026, giving you ample time to make an informed decision. As per SEBI guidelines, always remember that investing in IPOs involves market risks. You can View Full Sahajanand Medical IPO Details for a comprehensive understanding.